Mode
Text Size
Log in / Sign up

TREM2 activation lowers amyloid plaques and tau in Alzheimer's disease animal models across twelve studiesBoosting TREM2 activity helps clear brain plaques and improves memory in mouse models of Alzheimer's disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
TREM2 activation significantly reduces amyloid and tau pathology and reverses cognitive impairment in preclinical Alzheimer's disease models.

This systematic review and meta-analysis evaluated the impact of TREM2 activation on Alzheimer's disease pathology using twelve preclinical studies involving APP/PS1, 5XFAD, and Tau transgenic mice. The primary focus was on reducing amyloid beta and tau pathologies, with secondary outcomes assessing cognitive function. Results consistently demonstrated significant reductions in amyloid plaque numbers and area across the analyzed models.

Specifically, TREM2 overexpression led to a standardized mean difference of -0.87 for plaque numbers and -0.98 for plaque area. When using TREM2 agonist antibodies, the reduction in plaque numbers was even more pronounced, with a standardized mean difference of -2.03. Additionally, levels of insoluble amyloid beta42 and phosphorylated tau were decreased in the treated groups compared to controls.

Beyond pathological markers, cognitive impairment was reversed in the animal models receiving TREM2 interventions. While the overall certainty of evidence reflects a moderate risk of bias due to inadequate randomization and blinding, the findings highlight the potential of stage-specific and pathology-stratified strategies in translational research for Alzheimer's disease.

Scientists looked at twelve different studies involving mice with Alzheimer's disease. These animals had specific genes changed to mimic human brain problems. The researchers tested what happened when they made a protein called TREM2 work better in these mice.

When TREM2 activity went up, the number of sticky protein clumps in the brain went down significantly. These clumps are known to cause memory loss and confusion. The studies found that both the amount and size of these clumps were much smaller in the treated mice.

The treatment also helped lower levels of another harmful protein called Tau. Most importantly, the mice that received the treatment showed better memory skills. They were able to learn and remember things just like healthy mice do.

While this is very promising for mice, it does not mean the same will happen in people yet. The study notes that more careful testing is needed before trying this in humans. Researchers say we must be very careful about how we test new treatments for brain diseases.

What this means for you:
Boosting TREM2 works in mice to clear brain plaques and fix memory, but human testing is still required.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) deposition, hyperphosphorylated Tau accumulation, and chronic neuroinflammation, with microglial function playing a crucial role in modulating these pathological cascades. The microglial receptor TREM2 has emerged as a key regulator of microglial responses to AD-related pathology, and gain-of-function strategies targeting TREM2 have shown substantial therapeutic potential in preclinical models. However, outcomes of these strategies on Aβ and Tau pathologies have exhibited marked heterogeneity across studies, and no systematic integration of the relevant evidence so far. This deficiency has substantially hindered the rational development and clinical translation of TREM2-targeted therapeutic strategies. The objective of this study is to evaluate the effects of TREM2-targeted interventions on Aβ and Tau pathologies in AD animal models. A systematic search of PubMed, Embase, and Cochrane Library identified studies using AD animal models with TREM2-targeted interventions and reporting Aβ or Tau outcomes. This review was registered in PROSPERO (CRD420251131147). A total of 12 studies were included, with overall moderate risk of bias, mainly due to inadequate randomization and blinding. In APP/PS1 mice, TREM2 overexpression significantly reduced Aβ plaque number (SMD =  - 0.87; 95% CI, - 1.28 to - 0.47) and plaque area (SMD =  - 0.98; 95% CI, - 1.46 to - 0.50), with more pronounced effects observed in younger mice (≤ 7 months), where reductions in insoluble Aβ42 were also observed; phosphorylated Tau levels decreased as well. TREM2 agonist antibodies also reduced Aβ plaque number (SMD =  - 2.03; 95% CI, - 2.83 to - 1.24). However, effects on Aβ plaque area, insoluble and soluble Aβ isoforms levels were inconsistent. Antibody treatment also attenuated Tau pathology and Aβ pathology in certain models, including 5XFAD mice or Tau transgenic mice. In addition, both TREM2 overexpression and agonist antibodies could reverse the cognitive impairment of AD animal models. This systematic review and meta-analysis provides the first comprehensive synthesis of preclinical evidence supporting TREM2 gain-of-function modulation as an AD therapeutic strategy targeting both Aβ and Tau pathologies. Our findings reveal that therapeutic efficacy is governed by disease stage, model pathological complexity, and intervention mode. These insights highlight the need for developing stage-specific and pathology-stratified strategies in translational research, establishing TREM2 as a condition-dependent yet promising immunotherapeutic target for AD.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.